Myocardial ischemic postconditioning (PosC) describes an acquired resistance to lethal ischemia-reperfusion (I/R) injury afforded by brief episodes of I/R applied immediately after the ischemic insult. Cardioprotection is conveyed by parallel signaling pathways converging to prevent mitochondria permeability transition. Recent observations indicated that PostC is associated with free radicals generation, including nitric oxide (NO.) and superoxide (O2.-), and that cardioprotection is abrogated by antioxidants. Since NO. And O2. - react to form peroxynitrite, we hypothesized that postC might trigger the formation of peroxyntrite to promote cardioprotection in vivo. Rats were exposed to 45 min of myocardial ischemia followed by 3h reperfusion. PostC (3 cycles of 30 seconds ischemia/30 seconds reperfusion) was applied at the end of index ischemia. In a subgroup of rats, the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulphonatophenyl) porphyrinato iron (FeTPPS) was given intravenously (10 mg/kg-1) 5 minutes before PostC. Myocardial nitrotyrosine was determined as an index of peroxynitrite formation. Infarct size (colorimetric technique and plasma creatine kinase-CK-levels) and left ventricle (LV) function (micro-tip pressure transducer), were determined. A significant generation of 3-nitrotyrosine was detected just after the PostC manoeuvre. PostC resulted in a marked reduction of infarct size, CK release and LV systolic dysfunction. Treatment with FeTPPS before PostC abrogated the beneficial effects of PostC on myocardial infarct size and LV function. Thus, peroxynitrite formed in the myocardium during PostC induces cardioprotective mechanisms improving both structural and functional integrity of the left ventricle exposed to ischemia and reperfusion in vivo.
References
[1]
Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135. doi:10.1056/NEJMra071667. PubMed: 17855673.
[2]
Sanada S, Komuro I, Kitakaze M (2011) Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 301: H1723-H1741. doi:10.1152/ajpheart.00553.2011. PubMed: 21856909.
[3]
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP et al. (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588. PubMed: 12860564.
[4]
Mewton N, Bochaton T, Ovize M (2013) Postconditioning the heart of ST-elevation myocardial infarction patients. Circ J 77: 1123-1130. doi:10.1253/circj.CJ-13-0385. PubMed: 23575305.
[5]
Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D et al. (2010) Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423. doi:10.1093/cvr/cvq129. PubMed: 20448097.
[6]
Cohen MV, Downey JM (2011) Ischemic postconditioning: from receptor to end-effector. Antioxid Redox Signal 14: 821-831. doi:10.1089/ars.2010.3318. PubMed: 20518705.
[7]
Heusch G (2013) Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381: 166-175. doi:10.1016/S0140-6736(12)60916-7. PubMed: 23095318.
[8]
Penna C, Perrelli MG, Pagliaro P (2013) Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal 18: 556-599. doi:10.1089/ars.2011.4459. PubMed: 22668069.
[9]
Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C (2011) Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 14: 833-850. doi:10.1089/ars.2010.3245. PubMed: 20649460.
[10]
Penna C, Mancardi D, Rastaldo R, Pagliaro P (2009) Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta 1787: 781-793. doi:10.1016/j.bbabio.2009.02.008. PubMed: 19248760.
[11]
Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424. doi:10.1152/physrev.00029.2006. PubMed: 17237348.
[12]
Altug S, Demiryürek AT, Kane KA, Kanzik I (2000) Evidence for the involvement of peroxynitrite in ischaemic preconditioning in rat isolated hearts. Br J Pharmacol 130: 125-131. doi:10.1038/sj.bjp.0703280. PubMed: 10781007.
[13]
Altup S, Demiryürek AT, Ak D, Tungel M, Kanzik I (2001) Contribution of peroxynitrite to the beneficial effects of preconditioning on ischaemia-induced arrhythmias in rat isolated hearts. Eur J Pharmacol 415: 239-246. doi:10.1016/S0014-2999(01)00843-3. PubMed: 11275005.
[14]
Ferdinandy P, Schulz R (2003) Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543. doi:10.1038/sj.bjp.0705080. PubMed: 12598407.
[15]
Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J et al. (2009) Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 297: H1729-H1735. doi:10.1152/ajpheart.00484.2009. PubMed: 19734363.
[16]
Levrand S, Vannay-Bouchiche C, Pesse B, Pacher P, Feihl F et al. (2006) Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 41: 886-895. doi:10.1016/j.freeradbiomed.2006.04.034. PubMed: 16934671.
[17]
Liaudet L, Szabo E, Timashpolsky L, Virág L, Cziráki A et al. (2001) Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br J Pharmacol 133: 1424-1430. doi:10.1038/sj.bjp.0704185. PubMed: 11498530.
[18]
Loukili N, Rosenblatt-Velin N, Li J, Clerc S, Pacher P et al. (2011) Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc Res 89: 586-594. doi:10.1093/cvr/cvq373. PubMed: 21113057.
[19]
Manintveld OC, Te Lintel Hekkert M, van den Bos EJ, Suurenbroek GM, Dekkers DH et al. (2007) Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 292: H1551-H1560. PubMed: 17122197.
[20]
Penna C, Tullio F, Merlino A, Moro F, Raimondo S et al. (2009) Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 104: 390-402. doi:10.1007/s00395-008-0762-8. PubMed: 19030912.
[21]
Fantinelli JC, Mosca SM (2007) Comparative effects of ischemic pre and postconditioning on ischemia-reperfusion injury in spontaneously hypertensive rats (SHR). Mol Cell Biochem 296: 45-51. doi:10.1007/s11010-006-9296-2. PubMed: 16933149.
[22]
Shi W, Vinten-Johansen J (2012) Endogenous cardioprotection by ischaemic postconditioning and remote conditioning. Cardiovasc Res 94: 206-216. doi:10.1093/cvr/cvs088. PubMed: 22323534.
[23]
Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D et al. (2010) Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423. doi:10.1093/cvr/cvq129. PubMed: 20448097.
[24]
Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S et al. (2006) Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 101: 180-189. doi:10.1007/s00395-006-0584-5. PubMed: 16450075.
[25]
Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH (2007) Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci 81: 1223-1227. doi:10.1016/j.lfs.2007.08.031. PubMed: 17915258.
[26]
Lemoine S, Buléon C, Rouet R, Ivascau C, Babatasi G et al. (2010) Bradykinin and adenosine receptors mediate desflurane induced postconditioning in human myocardium: role of reactive oxygen species. BMC Anesthesiol 10: 12. doi:10.1186/1471-2253-10-12. PubMed: 20670410.
[27]
Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JC et al. (2013) Mitochondria as a Source of Reactive Oxygen and Nitrogen Species: From Molecular Mechanisms to Human Health. Antioxid Redox Signal 18: 2029-2074. doi:10.1089/ars.2012.4729. PubMed: 23244576.
[28]
González-Flecha B, Cutrin JC, Boveris A (1993) Time course and mechanism of oxidative stress and tissue damage in rat liver subjected to in vivo ischemia-reperfusion. J Clin Invest 91: 456-464. doi:10.1172/JCI116223. PubMed: 8432855.
[29]
Zweier JL, Wang P, Samouilov A, Kuppusamy P (1995) Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1: 804-809. doi:10.1038/nm0895-804. PubMed: 7585184.
[30]
Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107: 896-904. doi:10.1161/01.CIR.0000048192.52098.DD. PubMed: 12591762.
[31]
Pacher P, Schulz R, Liaudet L, Szabó C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310. doi:10.1016/j.tips.2005.04.003. PubMed: 15925705.
[32]
Liaudet L, Vassalli G, Pacher P (2009) Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci 14: 4809-4814. PubMed: 19273391.
[33]
Pesse B, Levrand S, Feihl F, Waeber B, Gavillet B et al. (2005) Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes. J Mol Cell Cardiol 38: 765-775. doi:10.1016/j.yjmcc.2005.02.020. PubMed: 15850570.
[34]
Balafanova Z, Bolli R, Zhang J, Zheng Y, Pass JM et al. (2002) Nitric oxide (NO) induces nitration of protein kinase Cepsilon (PKCepsilon ), facilitating PKCepsilon translocation via enhanced PKCepsilon -RACK2 interactions: a novel mechanism of no-triggered activation of PKCepsilon. J Biol Chem 277: 15021-15027. doi:10.1074/jbc.M112451200. PubMed: 11839754.
[35]
Liaudet L, Yang Z, Al-Affar EB, Szabó C (2001) Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. Mol Med 7: 406-417. PubMed: 11474134.
[36]
Nossuli TO, Hayward R, Scalia R, Lefer AM (1997) Peroxynitrite reduces myocardial infarct size and preserves coronary endothelium after ischemia and reperfusion in cats. Circulation 96: 2317-2324. doi:10.1161/01.CIR.96.7.2317. PubMed: 9337206.
[37]
Lefer DJ, Scalia R, Campbell B, Nossuli T, Hayward R et al. (1997) Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest 99: 684-691. doi:10.1172/JCI119212. PubMed: 9045871.
[38]
Levrand S, Pacher P, Pesse B, Rolli J, Feihl F et al. (2007) Homocysteine induces cell death in H9C2 cardiomyocytes through the generation of peroxynitrite. Biochem Biophys Res Commun 359: 445-450. doi:10.1016/j.bbrc.2007.05.147. PubMed: 17544363.
[39]
Duplain H, Sartori C, Dessen P, Jayet PY, Schwab M et al. (2008) Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice. J Physiol 586: 4011-4016. doi:10.1113/jphysiol.2008.154302. PubMed: 18591189.
[40]
Klassen SS, Rabkin SW (2009) The metalloporphyrin FeTPPS but not by cyclosporin A antagonizes the interaction of peroxynitrate and hydrogen peroxide on cardiomyocyte cell death. Naunyn Schmiedebergs Arch Pharmacol 379: 149-161. doi:10.1007/s00210-008-0342-3. PubMed: 18773197.
